title: [Pecularities for action of combined administration of NAN-190 and ketanserine with low dose of 17β-estradiol on depression-like behavior in prenatally stressed ovariectomized rats].
abstract: The aim of the present work was to perform a comparative analysis of 5-HT(1A)- and 5-HT(2A/2C)-receptors blockade effects on depression-like behavior of the adult ovariectomized (OVX) female offspring at estrogen deficiency delivered from their prenatally stressed mothers. The adult prenatally stressed OVX female offspring were chronically (during 14 days) treated by 5-HT(1A)-receptors antagonist--NAN-190 (0.1 mg/kg, s. c.) or 5-HT(2A/2C)-receptors antagonist--ketanserine (0.1 mg/kg, i. p.) alone, or in a combination with its preparartions a low dose of 17β-estradiol (5.0 μg/rat, s. c.). All drugs were administered in 2 weeks after overiectomy during 14 days before and for all period of behavioral testing procedure. The prenatally stressed QVX female offspring were tested in the forced swimming test (FST) and the open field test (OFT). Treatment with NAN-190 alone induced marked depressant-like effect, while NAN-190 administered in a combination with a low dose of 17β-estradiol resulted in an antidepressant-like effect in the FST in the prenatally stressed OVX females as compared to the control prenatally stressed female offspring. Administration ofNAN-190 plus 17β-estradiol led to decreased frequency of rearing, exploratory and grooming behavior in prenatally stressed OVX female offspring in the OFT. Treatment with ketanserine resulted in an antidepressant-like effect in prenatally stressed OVX females in the FST as compared to the control group. However, co-administration of ketanserine with a low dose of 17β-E2 to the prenatally stressed OVX female offspring failed to modify depressant-like behavior in the FST.
authors: Iu O
authors: IuO
authors: Fedotova
authors: S G
authors: SG
authors: Pivina
authors: V K
authors: VK
authors: Akulova
authors: N É
authors: NÉ
authors: Ordian
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D003863:Depression / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000494:pharmacology*; D004967:Estrogens / Q000172:deficiency; D005260:Female; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D007650:Ketanserin / Q000494:pharmacology*; D010052:Ovariectomy; D010879:Piperazines / Q000494:pharmacology*; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D051381:Rats; D017208:Rats, Wistar; D044282:Receptor, Serotonin, 5-HT1A / Q000378:metabolism; D044402:Receptor, Serotonin, 5-HT2A / Q000378:metabolism; D044405:Receptor, Serotonin, 5-HT2C / Q000378:metabolism; D012702:Serotonin Antagonists / Q000494:pharmacology*; D013312:Stress, Physiological; D013550:Swimming
chemical_list: D004967:Estrogens; D010879:Piperazines; D044402:Receptor, Serotonin, 5-HT2A; D044405:Receptor, Serotonin, 5-HT2C; D012702:Serotonin Antagonists; D044282:Receptor, Serotonin, 5-HT1A; C058895:1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine; D004958:Estradiol; D007650:Ketanserin